Janssen's IV Simponi wins FDA nod for rheumatoid arthritis

07/19/2013 | Medscape (free registration)

Janssen Biotech obtained the FDA's approval to market an intravenous formulation of Simponi Aria, or golimumab, in combination with methotrexate as a therapy for moderately to severely active rheumatoid arthritis. The drug, a tumor necrosis factor inhibitor, already was cleared for subcutaneous administration. The approval was based on data from a 592-patient, late-stage trial.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID